CBSC activates China manufacturing pipeline and advances MyCardia AT into final NMPA submission phase with Ebulent Medical.

Jan 15

Cardiac Biotech

Cardiac Biotech

Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase

CBSC activates China manufacturing pipeline and enters final NMPA submission phase for MyCardia AT cardiac monitoring device.

Sep 22

Cardiac Biotech

Cardiac Biotech

Completion of Asset Purchase Agreement and Commencement of its ECG Monitoring Business

An experienced executive management team is leading the way in the FDA and CE-cleared cardiac monitoring products and services arena, using smart phones and cloud-based software technology.

How can we help you?

Contact Us

© 2020-2026. Cardiac Biotech Solutions, Inc. - All rights reserved. | Designer

Get our news in your inbox!

Join our newsletter and we will send our news directly to you.